Pelabresib, a highly selective and effective BET bromodomain inhibitor, reduces the expression of BET-dependent genes in vivo and shows antitumor effects in MV-411 xenograft models; it is currently undergoing clinical trials for treating hematologic malignancies [93]. The gene discussed is DNER; the disease is hematologic disorder.